AU2019429147B2 - Treatment of AL amyloidosis with the combination of monoclonal antibodies against immunoglobulin light chains and the CD38 cell membrane molecule on antibody-producing and other immune cells - Google Patents

Treatment of AL amyloidosis with the combination of monoclonal antibodies against immunoglobulin light chains and the CD38 cell membrane molecule on antibody-producing and other immune cells Download PDF

Info

Publication number
AU2019429147B2
AU2019429147B2 AU2019429147A AU2019429147A AU2019429147B2 AU 2019429147 B2 AU2019429147 B2 AU 2019429147B2 AU 2019429147 A AU2019429147 A AU 2019429147A AU 2019429147 A AU2019429147 A AU 2019429147A AU 2019429147 B2 AU2019429147 B2 AU 2019429147B2
Authority
AU
Australia
Prior art keywords
ser
val
leu
seq
thr
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2019429147A
Other languages
English (en)
Other versions
AU2019429147A1 (en
Inventor
Nina Mercedes ASHTON
Raymond COMENZO
Wagner Zago
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Prothena Biosciences Ltd
Tufts Medical Center Inc
Original Assignee
Prothena Biosciences Ltd
Tufts Medical Center Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Prothena Biosciences Ltd, Tufts Medical Center Inc filed Critical Prothena Biosciences Ltd
Publication of AU2019429147A1 publication Critical patent/AU2019429147A1/en
Application granted granted Critical
Publication of AU2019429147B2 publication Critical patent/AU2019429147B2/en
Priority to AU2025200997A priority Critical patent/AU2025200997A1/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2896—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/42—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against immunoglobulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A61K2039/507—Comprising a combination of two or more separate antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Hematology (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oncology (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
AU2019429147A 2019-02-12 2019-12-16 Treatment of AL amyloidosis with the combination of monoclonal antibodies against immunoglobulin light chains and the CD38 cell membrane molecule on antibody-producing and other immune cells Active AU2019429147B2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2025200997A AU2025200997A1 (en) 2019-02-12 2025-02-13 Treatment of AL amyloidosis with the combination of monoclonal antibodies against immunoglobulin light chains and the CD38 cell membrane molecule on antibody-producing and other immune cells

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962804721P 2019-02-12 2019-02-12
US62/804,721 2019-02-12
PCT/US2019/066648 WO2020167376A1 (en) 2019-02-12 2019-12-16 Treatment of al amyloidosis with the combination of monoclonal antibodies against immunoglobulin light chains and the cd38 cell membrane molecule on antibody-producing and other immune cells

Related Child Applications (1)

Application Number Title Priority Date Filing Date
AU2025200997A Division AU2025200997A1 (en) 2019-02-12 2025-02-13 Treatment of AL amyloidosis with the combination of monoclonal antibodies against immunoglobulin light chains and the CD38 cell membrane molecule on antibody-producing and other immune cells

Publications (2)

Publication Number Publication Date
AU2019429147A1 AU2019429147A1 (en) 2021-09-09
AU2019429147B2 true AU2019429147B2 (en) 2024-11-14

Family

ID=69182616

Family Applications (2)

Application Number Title Priority Date Filing Date
AU2019429147A Active AU2019429147B2 (en) 2019-02-12 2019-12-16 Treatment of AL amyloidosis with the combination of monoclonal antibodies against immunoglobulin light chains and the CD38 cell membrane molecule on antibody-producing and other immune cells
AU2025200997A Withdrawn AU2025200997A1 (en) 2019-02-12 2025-02-13 Treatment of AL amyloidosis with the combination of monoclonal antibodies against immunoglobulin light chains and the CD38 cell membrane molecule on antibody-producing and other immune cells

Family Applications After (1)

Application Number Title Priority Date Filing Date
AU2025200997A Withdrawn AU2025200997A1 (en) 2019-02-12 2025-02-13 Treatment of AL amyloidosis with the combination of monoclonal antibodies against immunoglobulin light chains and the CD38 cell membrane molecule on antibody-producing and other immune cells

Country Status (17)

Country Link
US (2) US20220213223A1 (https=)
EP (1) EP3923954A1 (https=)
JP (2) JP2022520572A (https=)
KR (1) KR20210143752A (https=)
CN (2) CN119950702A (https=)
AU (2) AU2019429147B2 (https=)
BR (1) BR112021015870A2 (https=)
CA (1) CA3129890A1 (https=)
CL (1) CL2021002140A1 (https=)
EA (1) EA202192235A1 (https=)
IL (1) IL285480A (https=)
JO (1) JOP20210220A1 (https=)
MA (1) MA54923A (https=)
MX (1) MX2021009687A (https=)
PH (1) PH12021551960A1 (https=)
SG (1) SG11202108767PA (https=)
WO (1) WO2020167376A1 (https=)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PH12021552135A1 (en) 2019-03-05 2022-08-31 Prothena Biosciences Ltd Methods of treating al amyloidosis
MX2023000949A (es) 2020-07-23 2023-02-22 Othair Prothena Ltd Anticuerpos anti-beta-amiloide (abeta).

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030147882A1 (en) 1998-05-21 2003-08-07 Alan Solomon Methods for amyloid removal using anti-amyloid antibodies
US8263746B2 (en) 2004-02-06 2012-09-11 Morphosys Ag Anti-CD38 human antibodies and uses thereof
EP2567976B1 (en) 2005-03-23 2017-07-19 Genmab A/S Antibodies against CD38 for treatment of multiple myeloma
DK2237803T3 (en) 2007-12-28 2015-10-05 Prothena Biosciences Ltd Treatment and prophylaxis of amyloidosis
DK2580243T3 (da) 2010-06-09 2020-01-13 Genmab As Antibodies against human cd38
SG10201604104PA (en) 2011-10-25 2016-07-28 Prothena Therapeutics Ltd Antibody formulations and methods
AU2012328524B2 (en) 2011-10-28 2017-05-18 Excelse Bio, Inc. Protein formulations containing amino acids
MX389805B (es) * 2015-05-20 2025-03-11 Janssen Biotech Inc Anticuerpos anti-cd38 para el tratamiento de amiloidosis de cadena ligera y otras enfermedades malignas hematológicas positivas para cd38.
DK3827845T3 (da) 2015-11-03 2022-05-23 Janssen Biotech Inc Subkutane formuleringer af anti-cd38-antistoffer og anvendelser deraf
WO2018005967A1 (en) * 2016-06-30 2018-01-04 Prothena Therapeutics Limited Compositions for treating amyloidosis

Also Published As

Publication number Publication date
MA54923A (fr) 2021-12-22
JP2022520572A (ja) 2022-03-31
CN119950702A (zh) 2025-05-09
BR112021015870A2 (pt) 2021-11-03
MX2021009687A (es) 2021-12-10
SG11202108767PA (en) 2021-09-29
IL285480A (en) 2021-09-30
JP2025015588A (ja) 2025-01-30
CA3129890A1 (en) 2020-08-20
CN113924099A (zh) 2022-01-11
AU2019429147A1 (en) 2021-09-09
US20220213223A1 (en) 2022-07-07
EP3923954A1 (en) 2021-12-22
PH12021551960A1 (en) 2022-07-18
WO2020167376A8 (en) 2020-10-29
CL2021002140A1 (es) 2022-04-18
EA202192235A1 (ru) 2022-01-19
WO2020167376A1 (en) 2020-08-20
JOP20210220A1 (ar) 2023-01-30
AU2025200997A1 (en) 2025-03-13
KR20210143752A (ko) 2021-11-29
US20250075007A1 (en) 2025-03-06

Similar Documents

Publication Publication Date Title
AU2019277138B2 (en) Multi-specific binding proteins and improvements thereon
AU2018219887B2 (en) Multi-specific binding proteins for activation of natural killer cells and therapeutic uses thereof to treat cancer
AU2017228055B2 (en) Antibodies specific to human poliovirus receptor (PVR)
AU2017384687B2 (en) Bispecific anti-TNF-related apoptosis-inducing ligand receptor 2 and anti-cadherin 17 binding molecules for the treatment of cancer
AU2023274207A1 (en) FGFR2 inhibitors alone or in combination with immune stimulating agents in cancer treatment
AU2019218271B2 (en) Anti-cancer regimen using anti-CD47 and anti-CD20 antibodies
AU2018263837B2 (en) Stable formulations of anti-CTLA4 antibodies alone and in combination with programmed death receptor 1 (PD-1) antibodies and methods of use thereof
AU2017267793B2 (en) Single chain variable fragment CD3 binding proteins
AU2018247797B2 (en) Anti-LAG3 antibodies
AU2016383475B2 (en) Variable regions for NKp46 binding proteins
AU2020212767B2 (en) Combined pharmaceutical composition for treating tumor
AU2016368469B2 (en) Type II anti-CD20 antibody for reducing formation of anti-drug antibodies
AU2016340989B2 (en) Anti-IL-2 antibodies and compositions and uses thereof
JP6276175B2 (ja) 潜在的有害作用リスクのある患者にＣＤ１９ｘＣＤ３二特異性抗体を投与するための投薬レジメン
AU2017218415B2 (en) Novel anti-LAM and anti-PIM6/LAM monoclonal antibodies for diagnosis and treatment of mycobacterium tuberculosis infections
AU2019295279B2 (en) Antibody binding to cell adhesion molecule 3
AU2017224122B2 (en) Connexin (Cx) 43 hemichannel-binding antibodies and uses thereof
AU2019214865B2 (en) Mutant anti-CTLA-4 antibodies with improved immunotherapeutic effect but attenuated adverse effects
JP2018500384A (ja) 腫瘍形成を治療するための治療の組合せ
US20250075007A1 (en) Treatment of Al Amyloidosis with the Combination of Monoclonal Antibodies Agains Immunoglobulin Light Chains and the CD38 Cell Membrane Molecule on Antibody-Producing And Other Immune Cells
AU2021301921B2 (en) Bispecific antibody and use thereof
CA2475529A1 (en) Methods for treating chronic obstructive pulmonary disease (copd)
AU2017305502B2 (en) Combination of glucagon receptor antagonists and PI3K pathway inhibitors for the treatment of cancer
AU2021264421B2 (en) Compounds and methods targeting interleukin-34
AU2022219332A1 (en) Anti-cd112r antibody and use thereof

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)